Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A IgG4-related disease that involves the eye.
Biomarker and diagnostic research for IgG4-related ophthalmic disorder has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for IgG4-related ophthalmic disorder.
122 publications have been identified in PubMed for IgG4-related ophthalmic disorder. Research spans Case Report / Case Series (41%), Diagnostic / Biomarker (18%), and Review / Meta-Analysis (16%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 50 | 41% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 1:48 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about IgG4-related ophthalmic disorder
Testing and diagnosis research
22 |
18% |
Research summaries | 20 | 16% |
Disease patterns and progression | 11 | 9% |
Laboratory research | 9 | 7% |
Clinical study results | 7 | 6% |
Other research | 2 | 2% |
New treatment approaches | 1 | 1% |
Ren T (2026). [PMID: 41741699](https://pubmed.ncbi.nlm.nih.gov/41741699/). *Eye (London, England)*. [Clinical Trial Publication]
Hu J (2026). [PMID: 41588541](https://pubmed.ncbi.nlm.nih.gov/41588541/). *Arthritis research & therapy*. [Basic Science / Preclinical]
Weng W (2026). [PMID: 41756276](https://pubmed.ncbi.nlm.nih.gov/41756276/). *Frontiers in immunology*. [Review / Meta-Analysis]
Silva SHB (2026). [PMID: 41773762](https://pubmed.ncbi.nlm.nih.gov/41773762/). *Ophthalmic Plast Reconstr Surg*. [Case Report / Case Series]
Moreker MR (2026). [PMID: 41581048](https://pubmed.ncbi.nlm.nih.gov/41581048/). *Indian journal of ophthalmology*. [Clinical Trial Publication]
Arora P (2026). [PMID: 41640499](https://pubmed.ncbi.nlm.nih.gov/41640499/). *Neuroophthalmology*. [Case Report / Case Series]
Liu S (2026). [PMID: 41949825](https://pubmed.ncbi.nlm.nih.gov/41949825/). *Orbit*. [Case Report / Case Series]
Tian T (2026). [PMID: 41790699](https://pubmed.ncbi.nlm.nih.gov/41790699/). *Medicine*. [Case Report / Case Series]
Liu R (2026). [PMID: 41853890](https://pubmed.ncbi.nlm.nih.gov/41853890/). *The FEBS journal*. [Case Report / Case Series]
Cai R (2026). [PMID: 41460139](https://pubmed.ncbi.nlm.nih.gov/41460139/). *Indian journal of ophthalmology*. [Diagnostic / Biomarker]
AI-curated news mentioning IgG4-related ophthalmic disorder
Updated Jul 30, 2026
The future of rare disease clinical development is being shaped by regulatory innovation and adaptive trial designs, emphasizing the need for operational strategies to tackle challenges like limited patient populations and complex endpoints. Advances in artificial intelligence and global patient recruitment are also key to enhancing the development process.